Risdiplam (Evrysdi), A Small Molecule, SMN2 ‐Directed RNA Splicing Modifier for Treating Spinal Muscular Atrophy
Author:
- Jie Jack LiJLJie Jack Li
- 22 September 2022
- book chapter
- Published by Wiley
- p. 287-303
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- New treatments in spinal muscular atrophy: an overview of currently available dataExpert Opinion on Pharmacotherapy, 2020
- Structural basis of a small molecule targeting RNA for a specific splicing correctionNature Chemical Biology, 2019
- Rewriting the (tran)script: Application to spinal muscular atrophy2019
- Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA)Journal of Medicinal Chemistry, 2018
- Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)2018
- Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular AtrophyJournal of Medicinal Chemistry, 2017
- Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular AtrophyJournal of Medicinal Chemistry, 2016
- Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular AtrophyJournal of Medicinal Chemistry, 2016
- SMN2 splice modulators enhance U1–pre-mRNA association and rescue SMA miceNature Chemical Biology, 2015
- SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophyScience, 2014